The life sciences and medical devices industries have no shortage of ambitious strategies. Boards approve sweeping transformation programmes. Leadership teams craft compelling narratives about growth, efficiency, and patient impact. Consultants deliver polished decks. And yet, year after year, a striking proportion of these strategies fail not in their conception but in their execution. The ideas are sound. The implementation is not.
This gap between strategy and outcome is not unique to life sciences — but the consequences here are more acute. A failed commercial launch at a pharma company is not just a missed revenue target; it may mean patients waiting longer for a new therapy. A stalled operational transformation at a medical device manufacturer is not just an efficiency problem; it may compromise product quality and regulatory standing. Understanding why execution fails — and how to fix it — is therefore one of the most consequential management questions in the sector.
Why Execution Fails
In our experience working across pharma, biotech, and medical device companies, execution failures tend to cluster around a recognisable set of root causes:
- Strategy Without Operational Translation: Many strategies remain at an altitude that is inspiring but unactionable. A global pharma company may commit to "becoming the leader in patient-centric oncology" without ever translating that ambition into concrete changes to its commercial model, supply chain, or medical affairs function. Strategy that cannot be converted into specific decisions, resource allocations, and behavioural changes is a vision statement, not a plan.
- Misaligned Incentives: Even when the strategy is clear, execution stalls if the incentive structures reward different behaviours. A medical device company pursuing a services-led growth model will struggle if its salesforce is still compensated purely on device volume. A pharma company committed to cross-functional collaboration will find that commitment tested if business units are competing for the same P&L targets. People follow incentives — and if incentives point in a different direction from the strategy, incentives win.
- Underestimating Change Management: Transformation programmes in life sciences routinely underinvest in change management. The assumption — often implicit — is that once leadership endorses a new direction, the organisation will follow. It rarely does. At a major European medical device group, a multi-year ERP implementation delivered on time and on budget, yet adoption remained stubbornly low eighteen months post go-live because the change management programme had been scoped at a fraction of the technical investment. The system worked. The people did not change.
- Initiative Overload: Life sciences organisations are particularly prone to launching too many initiatives simultaneously. A mid-size pharma company we worked with had 47 active transformation workstreams at the point of engagement — each with a sponsor, a budget, and a project manager, but collectively consuming far more leadership attention and organisational bandwidth than was available. The result was a portfolio of half-executed initiatives, each moving slowly, few reaching completion. Priority is not about what you say yes to; it is about what you say no to.
- Weak Governance and Accountability: Execution requires someone to be accountable — not collectively responsible, but personally accountable. In matrix organisations, which are the norm in large pharma and device companies, accountability diffuses. Programme steering committees meet quarterly. Escalation paths are unclear. Decisions that require cross-functional trade-offs linger unresolved for months. By the time the problem surfaces at the right level, the window to correct course has often closed.
- Loss of Momentum: Strategies are typically launched with energy and commitment. That momentum is fragile. Leadership changes, budget cycles, regulatory setbacks, or simply the passage of time erode the organisational will to sustain difficult change. At a global biotech company, a commercial transformation that had strong initial traction lost momentum after a change in regional leadership — and was quietly deprioritised before its most important elements had been embedded.
How to Fix It
There is no single intervention that guarantees execution success. But the companies that consistently translate strategy into outcomes share a set of deliberate practices:
- Translate Strategy into the Operating Model: Every strategic priority should have a clear owner, a defined set of changes to processes, structures, and capabilities, and measurable milestones. A useful test: if you cannot describe what will be different — specifically — in the way the organisation operates twelve months from now, the strategy has not yet been translated into execution.
- Align Incentives Ruthlessly: Review compensation, performance management, and resource allocation through the lens of the strategy. If the metrics and rewards do not reinforce the strategic priorities, change them. This is uncomfortable work — it requires confronting legacy structures and vested interests — but without it, execution will always be swimming against the current.
- Invest in Change Management as a First-Class Discipline: Change management is not a communications plan. It is a structured programme to shift behaviours, build capabilities, and sustain adoption. In our experience, life sciences companies that invest 15–20% of programme budgets in change management consistently outperform those that treat it as an afterthought. For medical device companies navigating regulatory change or ERP transformation, this investment is particularly critical.
- Ruthlessly Prioritise: Limit the number of strategic initiatives in flight at any one time. A useful heuristic: the number of initiatives your organisation can execute well is probably half the number currently underway. Stopping initiatives is as important as starting them — and significantly harder. Build the governance discipline to say no.
- Establish Clear Accountability: For every critical initiative, there should be a single named owner with the authority, resources, and mandate to deliver. Steering committees advise; they do not own. Where cross-functional decisions are required, establish clear decision rights and escalation protocols in advance — not at the moment of conflict.
- Manage Momentum Actively: Sustaining execution energy over multi-year programmes requires deliberate effort. Celebrate intermediate milestones. Maintain visibility of progress at the senior level. Connect the work to the patient and clinical outcomes it is ultimately designed to serve — in life sciences, this is a particularly powerful source of organisational motivation. And when leadership changes, invest explicitly in continuity: the incoming leader needs to understand not just the strategy but the execution context.
- Build Execution Capability as a Core Competence: The most resilient life sciences organisations treat execution as a capability to be developed and sustained, not a one-time effort. This means investing in programme management talent, building internal consulting capabilities, and creating institutional knowledge about how change happens in the organisation — what works, what does not, and why.
Strategy execution is not glamorous work. It does not generate headlines or feature prominently in investor presentations. But it is the discipline that determines whether the ambitions of life sciences companies — ambitions that ultimately serve patients and healthcare systems — are realised or remain aspirational. In a sector where the stakes are as high as they are in pharma and medical devices, closing the gap between strategy and execution is not a management nicety. It is a leadership imperative.